133 related articles for article (PubMed ID: 389551)
1. Lipoprotein-X.
Narayanan S
CRC Crit Rev Clin Lab Sci; 1979 Aug; 11(1):31-51. PubMed ID: 389551
[TBL] [Abstract][Full Text] [Related]
2. Biochemistry and clinical relevance of lipoprotein X.
Narayanan S
Ann Clin Lab Sci; 1984; 14(5):371-4. PubMed ID: 6476782
[TBL] [Abstract][Full Text] [Related]
3. Role of lecithin:cholesterol acyltransferase and apolipoprotein A-I in cholesterol esterification in lipoprotein-X in vitro.
O K; Frohlich J
J Lipid Res; 1995 Nov; 36(11):2344-54. PubMed ID: 8656072
[TBL] [Abstract][Full Text] [Related]
4. Lipoprotein-X fifty years after its original discovery.
Fellin R; Manzato E
Nutr Metab Cardiovasc Dis; 2019 Jan; 29(1):4-8. PubMed ID: 30503707
[TBL] [Abstract][Full Text] [Related]
5. Plasma lipoprotein-X quantification on filipin-stained gels: monitoring recombinant LCAT treatment ex vivo.
Freeman LA; Shamburek RD; Sampson ML; Neufeld EB; Sato M; Karathanasis SK; Remaley AT
J Lipid Res; 2019 May; 60(5):1050-1057. PubMed ID: 30808683
[TBL] [Abstract][Full Text] [Related]
6. Familial lecithin:cholesterol acyltransferase deficiency: further resolution of lipoprotein particle heterogeneity in the low density interval.
Guérin M; Dolphin PJ; Chapman MJ
Atherosclerosis; 1993 Dec; 104(1-2):195-212. PubMed ID: 8141844
[TBL] [Abstract][Full Text] [Related]
7. [Studies on the structure and metabolism of lipoprotein-X (LP-X), the abnormal plasmalipoprotein in cholestasis (author's transl)].
Seidel D
Klin Wochenschr; 1977 Jul; 55(13):611-23. PubMed ID: 197298
[TBL] [Abstract][Full Text] [Related]
8. In vivo and in vitro relationship between lipoprotein-X and bile salts in cholestasis.
Frisón JC; Ras MR; Rubiés-Prat J; Salvá JA; Masdeu S; Bacardí R
Digestion; 1979; 19(6):411-4. PubMed ID: 535670
[TBL] [Abstract][Full Text] [Related]
9. LCAT protects against Lipoprotein-X formation in a murine model of drug-induced intrahepatic cholestasis.
Amar MJA; Freeman LA; Nishida T; Sampson ML; Pryor M; Vaisman BL; Neufeld EB; Karathanasis SK; Remaley AT
Pharmacol Res Perspect; 2020 Feb; 8(1):e00554. PubMed ID: 31893124
[TBL] [Abstract][Full Text] [Related]
10. A lipoprotein characterizing obstructive jaundice. I. Method for quantitative separation and identification of lipoproteins in jaundiced subjects.
Seidel D; Alaupovic P; Furman RH
J Clin Invest; 1969 Jul; 48(7):1211-23. PubMed ID: 4978447
[TBL] [Abstract][Full Text] [Related]
11. [The significance of LP-X cholesterol in the differential diagnosis of cholestasis (author's transl)].
Wieland H; Meissner-Heins H; Heins C; Seidel D
Klin Wochenschr; 1982 Apr; 60(7):343-8. PubMed ID: 7078029
[TBL] [Abstract][Full Text] [Related]
12. Appearance and characterization of lipoprotein X during continuous intralipid infusions in the neonate.
Griffin E; Breckenridge WC; Kuksis A; Bryan MH; Angel A
J Clin Invest; 1979 Dec; 64(6):1703-12. PubMed ID: 227938
[TBL] [Abstract][Full Text] [Related]
13. A lipoprotein characterizing obstructive jaundice. II. Isolation and partial characterization of the protein moieties of low density lipoproteins.
Seidel D; Alaupovic P; Furman RH; McConathy WJ
J Clin Invest; 1970 Dec; 49(12):2396-407. PubMed ID: 5480863
[TBL] [Abstract][Full Text] [Related]
14. Changes in the concentration of lipoprotein-X during incubation of postheparin plasma from patients with familial lecithin: cholesterol acyltransferase (LCAT) deficiency.
Ritland S; Stokke KT; Gjone E
Clin Chim Acta; 1976 Feb; 67(1):63-9. PubMed ID: 815065
[TBL] [Abstract][Full Text] [Related]
15. Lipoprotein-X in patients with cirrhosis: its relationship to cholestasis and hypercholesterolemia.
Sörös P; Böttcher J; Maschek H; Selberg O; Müller MJ
Hepatology; 1998 Nov; 28(5):1199-205. PubMed ID: 9794902
[TBL] [Abstract][Full Text] [Related]
16. Lecithin--cholesterol acyltransferase and the lipoprotein abnormalities of obstructive jaundice.
Agorastos J; Fox C; Harry DS; McIntyre N
Clin Sci Mol Med; 1978 Apr; 54(4):369-79. PubMed ID: 205385
[TBL] [Abstract][Full Text] [Related]
17. Lipoprotein-X: a substrate for lecithin: cholesterol acyltransferase.
Patsch JR; Soutar AK; Morrisett JD; Gotto AM; Smith LC
Eur J Clin Invest; 1977 Jun; 7(3):213-7. PubMed ID: 196860
[TBL] [Abstract][Full Text] [Related]
18. Formation of lipoprotein-X. Its relationship to bile compounds.
Manzato E; Fellin R; Baggio G; Walch S; Neubeck W; Seidel D
J Clin Invest; 1976 May; 57(5):1248-60. PubMed ID: 816809
[TBL] [Abstract][Full Text] [Related]
19. [Abnormal lipoprotein (LP-X) in the first months of life with particular reference to obstructive jaundice (author's transl)].
Lachmann D
Wien Klin Wochenschr Suppl; 1977; 69():3-28. PubMed ID: 266315
[TBL] [Abstract][Full Text] [Related]
20. Abnormal lipoprotein appearing in plasma of patients who received a ten percent soybean oil emulsion infusion.
Miyahara T; Fujiwara H; Yae Y; Okano H; Okochi K; Torisu M
Surgery; 1979 May; 85(5):566-74. PubMed ID: 107609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
